ICON PLC (NASDAQ:ICLR) has earned an average rating of “Buy” from the twelve analysts that are currently covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $96.00.
Several equities research analysts recently issued reports on ICLR shares. Mizuho started coverage on shares of ICON PLC in a research note on Thursday, March 23rd. They issued a “neutral” rating and a $66.00 target price for the company. Jefferies Group LLC upgraded shares of ICON PLC from a “hold” rating to a “buy” rating and raised their target price for the company from $86.00 to $117.00 in a research note on Thursday, June 29th. Credit Suisse Group reiterated an “outperform” rating and issued a $102.00 target price (up from $91.00) on shares of ICON PLC in a research note on Tuesday, June 6th. Zacks Investment Research downgraded shares of ICON PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, April 26th. Finally, Robert W. Baird cut their target price on shares of ICON PLC from $107.00 to $97.00 and set an “outperform” rating for the company in a research note on Friday, June 9th.
ILLEGAL ACTIVITY NOTICE: “Brokerages Set ICON PLC (ICLR) PT at $96.00” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/07/20/brokerages-set-icon-plc-iclr-pt-at-96-00.html.
A number of large investors have recently modified their holdings of the company. Somerset Trust Co boosted its position in shares of ICON PLC by 0.4% in the first quarter. Somerset Trust Co now owns 5,638 shares of the medical research company’s stock worth $449,000 after buying an additional 24 shares during the period. Cim LLC boosted its position in shares of ICON PLC by 4.6% in the first quarter. Cim LLC now owns 6,095 shares of the medical research company’s stock worth $486,000 after buying an additional 270 shares during the period. UBS Asset Management Americas Inc. boosted its position in shares of ICON PLC by 43.0% in the fourth quarter. UBS Asset Management Americas Inc. now owns 234,818 shares of the medical research company’s stock worth $17,659,000 after buying an additional 70,654 shares during the period. Legato Capital Management LLC boosted its position in shares of ICON PLC by 7,872.0% in the first quarter. Legato Capital Management LLC now owns 6,078,411 shares of the medical research company’s stock worth $76,247,000 after buying an additional 6,002,164 shares during the period. Finally, Farmers & Merchants Investments Inc. boosted its position in shares of ICON PLC by 11.5% in the first quarter. Farmers & Merchants Investments Inc. now owns 51,236 shares of the medical research company’s stock worth $4,085,000 after buying an additional 5,269 shares during the period. Hedge funds and other institutional investors own 92.64% of the company’s stock.
Shares of ICON PLC (NASDAQ ICLR) traded down 0.41% during mid-day trading on Monday, hitting $99.80. The company’s stock had a trading volume of 164,770 shares. The company has a 50-day moving average price of $97.02 and a 200-day moving average price of $86.38. ICON PLC has a 1-year low of $70.68 and a 1-year high of $101.40. The stock has a market cap of $5.37 billion, a PE ratio of 20.71 and a beta of 0.59.
ICON PLC (NASDAQ:ICLR) last issued its earnings results on Thursday, April 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.02. ICON PLC had a net margin of 16.15% and a return on equity of 28.89%. The business had revenue of $432 million during the quarter, compared to the consensus estimate of $432.21 million. During the same period last year, the business posted $1.12 EPS. ICON PLC’s revenue was up 7.9% on a year-over-year basis. Analysts predict that ICON PLC will post $5.17 EPS for the current fiscal year.
ICON PLC Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for ICON PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON PLC and related companies with MarketBeat.com's FREE daily email newsletter.
